- A breast cancer vaccine has completed phase one trials, showing a strong immune response in over 75 per cent of participants.
- Developed by Anixa Biosciences and the Cleveland Clinic, the vaccine targets alpha-lactalbumin, a protein linked to aggressive triple-negative breast cancer, aiming to prevent and treat the disease.
- The trial involved 35 women, many with triple-negative breast cancer or genetic risk, with blood tests confirming a strong antibody response and only mild injection-site irritation.
- Researchers are hopeful the vaccine could help eradicate breast cancer by 2030, with Anixa’s CEO, Dr Amit Kumar, calling the findings “very exciting”.
- Phase two trials are scheduled for next year to test a larger group and additional breast cancer types, with the study funded by the US Department of Defence.
IN FULL
